Back to Search
Start Over
Structural studies of Mycobacterium tuberculosis DprE1 interacting with its inhibitors.
- Source :
-
Drug discovery today [Drug Discov Today] 2017 Mar; Vol. 22 (3), pp. 526-533. Date of Electronic Publication: 2016 Sep 22. - Publication Year :
- 2017
-
Abstract
- The flavoenzyme DprE1 catalyses a crucial step in arabinan production for cell wall biosynthesis in Mycobacterium tuberculosis and is a highly vulnerable drug target. It was first discovered using benzothiazinones (BTZ): exquisitely potent bactericidal agents that are being developed as drugs to treat tuberculosis. Subsequently, many compounds with diverse scaffolds were found to act as either covalent or noncovalent DprE1 inhibitors. Covalent inhibitors, like the BTZ, are all nitroaromatic compounds that serve as suicide substrates after DprE1-mediated nitroreduction. Here, we describe how high-resolution structures of DprE1, alone and in complex with various ligands, explain enzyme activity and inhibition.<br /> (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Subjects :
- Alcohol Oxidoreductases metabolism
Animals
Antitubercular Agents therapeutic use
Bacterial Proteins metabolism
Humans
Mycobacterium tuberculosis drug effects
Mycobacterium tuberculosis metabolism
Protein Conformation
Tuberculosis drug therapy
Alcohol Oxidoreductases antagonists & inhibitors
Alcohol Oxidoreductases chemistry
Antitubercular Agents pharmacology
Bacterial Proteins antagonists & inhibitors
Bacterial Proteins chemistry
Subjects
Details
- Language :
- English
- ISSN :
- 1878-5832
- Volume :
- 22
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Drug discovery today
- Publication Type :
- Academic Journal
- Accession number :
- 27666194
- Full Text :
- https://doi.org/10.1016/j.drudis.2016.09.014